Diese Veranstaltung hat bereits stattgefunden

Kongress

42nd Annual Macula Society Meeting

An event for ophthalmologists
FL 34134 Bonita Springs, USA
Veranstaltungsnummer: 25802
Zertifizierung: beantragt
Gebühren ab: gebührenfrei
verfügbare Plätze: unbegrenzt
Sprache: Englisch

 Zum Kalender hinzufügen
  • Datum
    13.02.2019 - 16.02.2019
    Veranstalter
    The Macula Society
    Kurzbeschreibung
    42nd Annual Macula Society Meeting 2019 will be held in Bonita Springs, Florida, USA. The meeting is open to members, their guests, co-authors and supporting company representatives. Further information will follow soon.
    Gebühren

    Fachärzte

    Teilnehmer max.
    unbegrenzt

    Gebühren ab
    k.A.
    Hinweis
    k.A.

    Ärzte/-innen in Weiterbildung

    Teilnehmer max.
    unbegrenzt

    Gebühren ab
    k.A.
    Hinweis
    k.A.
    Deadlines

    Abstract-Thema

    01.01.1970 Hinweis
  • Wednesday, February 13, 2019 SESSION I - Diabetic Retinopathy  
         
    4:25 p.m Multiethnic Genome-Wide Association Study of Diabetic Retinopathy Lucia Sobrin
    4:29 p.m DRGen Study: Novel Genetic Variants in Extreme and Advanced (Proliferative)
    Phenotypes of Diabetic Retinopathy
    Arup Das
    4:33 p.m. Risk Factors for Blindness in Patients With Diabetic Retinopathy: Lessons from
    the AAO IRIS® Registry
    Rahul Khurana
    4:37 p.m. Integrating Diabetic Eye Screening in a Haemodialysis Clinic Tunde Peto
    4:41 p.m. Discussion of Previous Four Papers  
    4:45 p.m. Is Cataract Surgery a Risk Factor for the Incidence and Progression of Age-Related
    Macular Degeneration and Diabetic Retinopathy?
    Tien Wong
    4:54 p.m Diabetic Retinopathy Outcomes in Untreated Fellow Eyes of Patients Receiving
    Ranibizumab in the RIDE/RISE Trials: The Road Less Traveled
    Sophie Bakri
    5:03 p.m. Patients Ultra-Responsive to Ranibizumab: Rates of >=4-Step Improvement in
    Diabetic Retinopathy Severity in DRCR.net Protocol S
    Sunir Garg
    5:12 p.m. Treatment of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy
    with Intravitreal Aflibercept Injection: Results from the Phase 3 PANORAMA Study
    David Brown
    5:21 p.m. Optical Coherence Tomography Angiography Confirms that Intravitreal Anti-Vascular
    Endothelial Growth Factor Can Diminish Signs of Diabetic Retinopathy Without
    Reducing Non-Perfusion
    Ramin Tadayoni
    5:30 p.m Post Hoc Exploratory Analysis of Humphrey Visual Field Changes Through Five
    Years in Eyes with Proliferative Diabetic Retinopathy
    Michael Elman
    5:39 p.m Anti-Vascular Endothelial Growth Factor Therapy and Risk of Traction Retinal
    Detachment in Eyes with Proliferative Diabetic Retinopathy: Post Hoc Analysis
    of Five DRCR.net Randomized Clinical Trials
    Justin Gottlieb
    5:50 p.m. Introduction and Presentation of the Lawrence J. Singerman Medal
    – Morton F. Goldberg, MD, FACS
     
    5:53 p.m. Award Recipient – Matthew D. Davis, MD (posthumous)  
         
      SESSION II - Oncology 1  
         
    6:00 p.m. Intravitreal and Intra-Arterial Chemotherapy Drug Discovery Using a
    Rabbit Model: Toxicity and Efficacy of Novel Compounds in Vivo
    Anthony Daniels
    6:04 p.m. Impact of Quantitative Genetic Ancestry on Precision Medicine in Uveal Melanoma J. William Harbour
    6:08 p.m. Discussion of Previous Two Papers  
         
      SESSION III - Imaging  
         
    6:15 p.m Ultra-Widefield Swept-Source OCT Imaging of Posterior Vitreous in Eyes with
    High Myopia
    Kyoko Ohno-Matsui
    6:24 p.m. Macular Pigment in Multiple Sclerosis Giovanni Staurenghi
    6:33 p.m Quantifying Organelles Serving as Signal Sources for Imaging of the Human
    Retinal Pigment Epithelium (RPE), via Volume Electron Microscopy
    Christine Curcio
    6:42 p.m Hyperspectral Autofluorescence (AF) Imaging for Detection of Drusen and
    Sub Retinal Pigment Epithelium (subRPE) deposits
    R. Theodore Smith
    6:46 p.m. Age-Related Changes in Autofluorescent (AF) Granules Accumulation of
    the Human Retinal Pigment Epithelium (RPE)
    Thomas Ach
    6:50 p.m. Diabetic Retinopathy Severity Level Assessment: Comparison of Seven-field
    Fundus Photographs to Ultrawide-Field Imaging
    Barbara Blodi
    6:54 p.m. Quantitative Comparison of Retinal Pixel Area Imaged by Ultra-Wide
    Field Fundus Cameras
    Ajay Kuriyan
    6:58 p.m. Retinal Vascular Geometry and the Subsequent Risk of Diabetes Gavin Tan
    7:02 p.m. Discussion of Previous Five Papers  
    7:07 p.m. Computational Fluid Dynamics Modeling of Diabetic Microaneurysms Identifies
    Blood Flow Parameters Associated with Clot Presence and Local Neural
    Retinal Disorganization
    Jennifer Sun
    7:16 p.m. Topographic Variations of Choroidal Thickness in Healthy Eyes on Swept Source
    Optical Coherence Tomography
    Alain Gaudric
    7:20 p.m. Remodeling of Macular Vortex Veins in Pachychoroid Neovasculopathy Shoji Kishi
    7:24 p.m.  Dynamic Changes in Choroidal Conditions During Anti-Vascular Endothelial
    Growth Factor Therapy in Polypoidal Choroidal Vasculopathy
    Yoko Ozawa
    7:28 p.m. Discussion of Previous Three Papers  
         
    7:32 p.m. Adjourn  
         
    Thursday, February 14, 2019 SESSION IV - OCT Angiography  
         
    7:30 a.m. Longitudinal Analaysis of Foveal Microvasculature Using OCT Angiography after
    Rhegmatogenous Retinal Detachment Surgery
    Seung-Young Yu
    7:39 a.m. How Abnormal is this FAZ? - Easier Detection of Diabetic FAZ Enlargement
    Comparing En Face OCT Vascular Patterns to OCT Angiography
    Richard Rosen
    7:46 a.m. Quantitative OCT Angiography Analysis for Classification and Staging of
    Non-Proliferative Diabetic Retinopathy
    Jennifer Lim
    7:53 a.m. Discussion of Previous Two Papers  
    7:57 a.m. 4D OCTA: Time-Resolved OCTA Can Visualize Chorioretinal Hemodynamics Nadia Waheed
    8:06 a.m. Choriocapillaris Flow Impairment Surrounding Geographic Atrophy Correlates
    with Disease Progression
    SriniVas Sadda
    8:13 a.m Relationship Between Choriocapillaris Flow Deficits Around Geographic
    Atrophy and Enlargement Rates Based on Swept Source OCT Imaging
    Philip Rosenfeld
    8:20 a.m. Discussion of Previous Two Papers  
    8:24 a.m. New Proposal for the Pathophysiology of Type 3 Neovascularization as
    Based on Multimodal Imaging Findings
    Richard Spaide
    8:33 a.m Sensitivity of OCT Angiography in the Detection of Choroidal Neovascularization
    in Wet AMD in Relation to Anatomical Features on SDOCT
    Aude Ambresin
    8:37 a.m. 3D Volumetric Analysis of Pigment Epithelial Detachment Progression in
    Neovascular AMD using En Face OCT Angiography
    David Sarraf
    8:44 a.m. Volume-Rendered Projection-Resolved OCT Angiography: 3D Lesion Complexity Is
    Associated With Therapy Response in Wet Age-Related Macular Degeneration
    Amani Fawzi
    8:51 a.m. Discussion of Previous Three Papers  
    8:55 a.m. Introduction and Presentation of the Young Investigator Lecture and Award
    – Eric H. Souied, MD, PhD
     
    8:58 a.m. Award Recipient and Lecture – Giuseppe Querques, MD, PhD  
    9:01 a.m. Discussion and Questions  
         
      SESSION V - Neovascular AMD I  
         
    9:15 a.m. Prospective Trial Comparing Intravitreal Aflibercept Injection (IAI) Using a Modified
    Treat-and-Extend (T&E) to Fixed Bi-Monthly Protocol for PCV: 6-Month Outcomes
    Gemmy Cheung
    9:24 a.m. Ten-Year Treatment Outcome of Polypoidal Choroidal Vasculopathy Using
    Photodynamic Therapy and Anti-Vascular Endothelial Growth Factor
    Won Ki Lee
    9:33 a.m. A Cost-Utility/Cost-Benefit Analysis of Bevacizumab, Ranibizumab & Aflibercept
    Monotherapy for Treating Neovascular Age-Related Macular Degeneration (NVAMD)
    Gary Brown
    9:37 a.m. Association Between Early Vision-Related Quality of Life Outcomes and Anatomic
    Dryness Response in Neovascular Age-Related Macular Degeneration (nAMD):
    A Post-Hoc Analysis of VIEW Trials
    Michael Singer
    9:41 a.m Higher-Order Optical Coherence Tomography (OCT) Fluid Burden Assessment: Analysis
    From OSPREY Matched Phase
    Justis Ehlers
    9:45 a.m. Discussion of Previous Three Papers  
    9:48 a.m. Intravitreal Aflibercept in a Routine Treat and Extend Regimen in Treatment-Naïve Wet
    AMD Patients: Prefinal 1-Year Outcome Data of the ASTERIA Study
    Stephan Michels
    9:57 a.m.  Brolucizumab Versus Aflibercept for Neovascular AMD: 48-Week Expanded Fluid
    Analyses from the HAWK and HARRIER Studies
    Peter Kaiser
    10:06 a.m Intravitreal (IVT) Delivery of a Novel Depot Formulation of Sunitinib (GB-102) in
    Patients With nAMD: Results of a Phase 1 First-in-Human Study
    Pravin Dugel
    10:15 a.m. Port Delivery System With Ranibizumab (PDS) in Neovascular AMD: How Ladder
    Phase 2 Results Informed Archway Phase 3 Design
    Dennis Marcus
    10:24 a.m. Phase I/II Randomized Study of Proton Beam with Anti-VEGF For Exudative
    Age-Related Macular Degeneration: Long-Term Results
    Susanna Park
         
    10:30 a.m. Break  
         
      SESSION VI - Deep Learning / Artificial Intelligence  
         
    10:50 a.m.  Deep Learning Predicts OCT Measures of Diabetic Macular Thickening From Color
    Fundus Photographs
    Anthony Adamis
    10:59 a.m. Deep Generative Models Creating High-Resolution Synthetic Retinal Images and
    Relevance to Humans and Machines
    Neil M. Bressler,
    11:08 a.m. DeepSeeNet: A Deep Learning Model for Automated Classification of Patient-Based
    Age-Related Macular Degeneration Severity from Color Fundus Photographs.
    Emily Chew
    11:17 a.m. Deep Learning in the Prediction of AMD Disease Progression Ursula Schmidt-Erfurth
    11:26 a.m. Automated Segmentation of Lesions in Neovascular AMD Hyung Chan Kim
    11:30 a.m. Prognostic Factors in Patients with Neovascular AMD or PCV from Clinical and OCT
    Parameters using a Convolutional Neural Network
    Hyewon Chung
    11:34 a.m.  Artificial Intelligence for Morphology-Based Function Prediction in Neovascular
    Age-Related Macular Degeneration
    Steffen Schmitz-Valckenberg
    11:38 a.m. Robustness of an Autonomous AI System for Detection of Diabetic Retinopathy Michael Abramoff
    11:42 a.m. Artificial Intelligence Deep Learning System for Measurement of Retinal
    Vascular Caliber
    Carol Cheung
    11:46 a.m Discussion of Previous Five Papers  
    11:50 a.m. Introduction and Presentation of the J. Donald M. Gass Medal – Carol L. Shields,
    MD, and Emily Y. Chew, MD
     
    11:53 a.m. Anthony AdamisAward Recipient – Usha Chakravarthy, MBBS, MD, PhD  
         
      SESSION VII - Dry AMD  
         
    12:00 p.m. Longitudinal Changes in Rod Function in Intermediate Age-Related Macular
    Degeneration With and Without Reticular Pseudodrusen
    Chi Luu
    12:04 p.m. Classification of Intermediate Age-Related Macular Degeneration by Short-Term
    Risk for Atrophy on Spectral Domain Optical Coherence Tomography
    Eleonora Lad
    12:08 p.m. The 9-Step Minnesota Grading System: A Model to Study Disease Pathogenesis Timothy Olsen
    12:12 p.m. Müller Cells and Choriocapillaris in the Pathogenesis of Geographic Atrophy
    Secondary to Age-Related Macular Degeneration
    Elisabetta Pilotto
    12:16 p.m. Taurocholic Acid Protects Against Age-Related Macular Degeneration in In Vitro Models Milam Brantley
    12:20 p.m. Discussion of Previous Five Papers  
    12:25 p.m. Choroidal Vascular Changes in Atrophic AMD: Relationship with Disease
    Stage and ARMS2 Genotype
    Robert Mullins
    12:34 p.m. Kamuvudines for Geographic Atrophy Jayakrishna Ambati
    12:43 p.m. The Fate and Prognostic Implications of Cholesterol Crystals in Non-Neovascular
    Age-Related Macular Degeneration
    K. Bailey Freund
    12:52 p.m. Cuticular Drusen: The Nature of Phenotype 3 Lawrence Yannuzzi
    1:01 p.m. Subthreshold Nanosecond Laser to Slow Progression of Intermediate Age-Related
    Macular Degeneration: The LEAD Trial Secondary Outcomes
    Robyn Guymer
    1:10 p.m. Photovoltaic Restoration of Central Vision in Patients with Geographic Atrophy José-Alain Sahel
         
    1:15 p.m Young Member Mentor Lecture Program  
         
    Friday, February 15, 2019    
         
    7:00 a.m. Business Meeting  
         
      SESSION VIII - Neovascular AMD II  
         
    7:50 a.m. Topical Inhibition of Runx1 Reduces Choroidal Neovascularization in Mice Leo Kim
    7:54 a.m. Anti-VEGF Monotherapy for Thick Submacular Hemorrhage Associated with Retinal
    Pigment Epithelial Detachment in Age-Related Macular Degeneration
    Jeffrey Gross
    7:58 a.m. Time to Maximum Response in Eyes with Neovascular AMD Treated with Ranibizumab Demetrios Vavvas
    8:02 a.m. Comparison of Intravitreal Silicone Oil Microdroplet Following Multiple Bevacizumab,
    Ranibizumab and Aflibercept Injections
    John Thompson
    8:06 a.m Discussion of Previous Four Papers  
    8:10 a.m Antagonism of Mineralocorticoids Inhibits Choroidal Neovascularization: Implication
    for Wet AMD
    Francine Behar-Cohen
    8:19 a.m Human Plasma Metabolomics in Age-Related Macular Degeneration
    – Meta-Analysis of Two Distinct Cohorts
    Joan Miller
    8:28 a.m. Is Drier Really Better in Neovascular Age-Related Macular Degeneration? Nancy Holekamp
    8:37 a.m A “Real World” Analysis of Visual Acuity Outcomes in 49,485 Eyes Receiving
    Anti-Vascular Endothelial Growth Factor Therapy for Neovascular AMD
    Thomas Ciulla
    8:46 a.m Real-World Analysis of Injection Frequency Following Wet AMD Diagnosis
    According to Baseline Visual Acuity
    Judy Kim
    8:55 a.m. Analysis of Anti-VEGF Injection Claims Data in Medicare Beneficiaries Following CATT Trial Paul Sternberg, Jr
         
      SESSION IX - Vitreo-Retinal Surgery  
         
    9:05 a.m. Central Retinal Artery Occlusion on Postoperative Day One after Vitreoretinal Surgery Harry Flynn
    9:09 a.m. Rotation in Retinal Nerve Fiber Layer Peak after Epiretinal Membrane Removal Hyeong Gon Yu
    9:13 a.m. Prospective Retinal and Optic Nerve Vitrectomy Evaluation (PROVE) Study:
    Five-Year Findings
    Stephen Kim
    9:17 a.m. Posterior Vitreous Mobility Delineated by Tracking of Optical Coherence
    Tomography Images in Eyes with Macular Holes
    Keisuke Mori
    9:21 a.m. Clinical Characteristics, Risk Factors, and Surgical Outcomes of a Secondary
    Macular Hole after Vitrectomy
    Min Kim
    9:25 a.m.  Discussion of Previous Five Papers  
    9:29 a.m. Comparative Study of Peeled Internal Limiting Membrane (ILM) Reposition and
    ILM Peeling in Idiopathic Macular Hole: A Randomized-Control Trial
    Peiquan Zhao
    9:38 a.m.  First Failed Macular Hole Surgery or Reopening of a Previously Closed Hole:
    Do we Gain by Re-Operating? – A Systematic Review and Meta Analysis
    Noemi Lois
    9:47 a.m. Connecting the Surgeon to OCT Image Guidance for Vitreoretinal Surgery Cynthia Toth
    9:56 a.m. Placing the Surgeon in the Center - Placing the Surgeon in the Center -
    A Novel 3D Visualization Platform for Retina Surgery Providing Transparent
    Display, Data Overlay and Guidance
    Anat Loewenstein
    10:05 a.m. Introduction and Presentation of the Paul Henkind Memorial Lecture and Award
    - Sophie J. Bakri, MD
     
    10:08 a.m. Paul Henkind Memorial Lecture and Award - Jose S. Pulido, MD, MS, MBA, MPH  
         
    10:25 a.m. Break  
         
      SESSION X - Diabetic Macular Edema  
         
    10:45 a.m. Müller Cells Activity is Restored and Retinal Inflammation Reduced by Subthreshold
    Micropulse Laser Treatment of Human Diabetic Macular Edema
    Edoardo Midena
    10:49 a.m. OCT Angiography Detects Early Microvascular Changes after Subthreshold
    Micropulse Laser in Diabetic Macular Edema
    Stela Vujosevic
    10:53 a.m. Two-year Outcomes of Ranibizumab Treatment for Diabetic Macular Edema.
    Data from the Fight Retinal Blindness! Project
    Daniel Barthelmes
    10:57 a.m. Vision Threatening Complications in Patients with Diabetic Macular Edema:
    A Post Hoc Analysis from the VISTA and VIVID Trials
    Ivan Suner
    11:01 a.m. Discussion of Previous Four Papers  
    11:05 a.m. A 12-month Prospective Study to Evaluate the Efficacy of Treat and Extend Regimen (T&E)
    of Intravitreal Aflibercept as a Second-Line Treatment for Diabetic Macular Edema (TADI Study)
    Itay Chowers
    11:14 a.m. Observation Versus Treatment in Diabetic Macular Edema with Very Good Visual Acuity
    – The OBTAIN Study
    Adrian Fung
    11:23 a.m. Relationship between Change in Visual Acuity and Change in Retinal Thickness during
    Treatment of Diabetic Macular Edema in Participants Randomized to Aflibercept,
    Bevacizumab or Ranibizumab
    Mathew MacCumber
    11:27 a.m. Visual Acuity with Habitual Correction on an Early Treatment Diabetic Retinopathy
    Study (ETDRS) Chart vs. Protocol Refraction on an Electronic ETDRS Chart in Eyes
    with Diabetic Macular Edema
    Susan Bressler
    11:31 a.m. Long-Term Intraocular Pressure Outcomes in Patients Receiving the 0.2 ug/day Fluocinolone
    Acetonide Intravitreal Implant
    Daniel Roth
    11:35 a.m. Discussion of Previous Three Papers  
    11:39 a.m. Suprachoroidal CLS-TA Plus Aflibercept Compared to Aflibercept Monotherapy for
    Diabetic Macular Edema: Results of the Randomized Phase 2 TYBEE Trial
    Charles Wykoff
    11:48 a.m. Dual Inhibition of Ang-2 and VEGF-A with Faricimab: Evidence for Increased Durability
    from the BOULEVARD Phase 2 Trial for Diabetic Macular Edema
    Caroline Baumal
         
      SESSION XI - Pediatric Retina and Inherited Retinal Diseases  
         
    12:00 p.m. Fluorescein Angiography Findings in Infants Treated With Intravitreal Bevacizumab
    for Retinopathy of Prematurity
    G. Baker Hubbard, III
    12:09 p.m. An Interesting Family with Achromatopsia J. Timothy Stout
    12:18 p.m. Longitudinal Changes in Scotopic and Mesopic Macular Function as Assessed with
    Microperimetry in Patients with Stargardt Disease – The SMART Study
    Hendrik Scholl
    12:27 p.m. Complement C5 Inhibition as a Potential Treatment for Autosomal Recessive Stargardt
    Disease (STGD1): Design of a Clinical Trial Assessing a Novel Treatment and
    Primary Outcome Measure
    Christine Kay
    12:36 p.m. Extracellular Matrix Disorders and Inherited Retinal Dystrophies Isabelle Meunier
    12:40 p.m. RDH12 Disease: A Severe Central Retinal Degeneration with Relatively
    Spared Rod Function
    Tomas Aleman
    12:44 p.m. Disease Stage Classification of Choroideremia for Clinical Treatment Trials
    and Clinical Practice
    Peter Francis
    12:48 p.m. Optical Coherence Tomography Angiography Assessment of Neurovascular
    Damage as Biomarker of Progression in Best Disease
    Maurizio Battaglia Parodi
    12:52 p.m. Discussion of Previous Four Papers  
    1:00 p.m.  Introduction and Presentation of the Arnall Patz Medal – Gregory S. Hageman, MD, PhD  
    1:03 p.m. Award Recipient – Mary Elizabeth Ruth Hartnett, MD, FACS, FARVO  
         
    1:15 p.m. Adjourn  
         
    Saturday, February 16, 2019 SESSION XII - Neuroprotection, Gene Therapy, Regenerative Medicine  
         
    7:30 a.m VMD2 Promoter Shows Optimal Specificity and Expression of Protective
    Rap1a in Retinal Pigment Epithelium
    Mary Elizabeth Hartnett
    7:39 a.m. A New Approach to Ocular Gene Therapy: Evaluation of Suprachoroidal
    Administration of Non-Viral DNA Nanoparticles in a Rabbit Model
    Szilard Kiss
    7:48 a.m. Progress Toward Gene Therapy for RPGR-Associated X-Linked Retinitis Pigmentosa Edwin Stone
    7:57 a.m. Change in Legal Blindness Status During the Phase 3 Voretigene Neparvovec-rzyl
    Study in Biallelic RPE65 Mutation–Associated Inherited Retinal Disease
    Julia Haller
    8:06 a.m. Optogenetics for Vision Restoration Sai Chavala
    8:15 a.m. Intraoperative Optical Coherence Tomographic Findings in Patients
    Undergoing Ocular Gene Therapy Surgery
    Andreas Lauer
    8:19 a.m. Surgical Implantation and In-Vivo Degradation of Fibrin Scaffolds within the Subretinal Space Raymond Iezzi
    8:23 a.m.  In-Vivo Imaging of Cone Photoreceptor Transplantation Mandeep Singh
    8:27 a.m. Neuroprotective Role of Hexokinase 2 in Photoreceptor Survival Cagri Besirli,
    8:31 a.m. Discussion of Previous Four Papers  
    8:35 a.m. Introduction and Presentation of the W. Richard Green Lecture and Award
    – Mary Elizabeth Ruth Hartnett, MD, FACS, FARVO
     
    8:38 a.m. W. Richard Green Lecture and Award – Paul S. Bernstein, MD, PhD  
    8:58 a.m. Introduction and Presentation of the Evangelos S. Gragoudas Lecture
    and Award – Neil M. Bressler, MD
     
    9:01 a.m. Evangelos S. Gragoudas Recipient Lecture and Award – Daniel Shu Wei Ting, MD, PhD  
    9:05 a.m. Introduction and Presentation of the Lawrence J. Singerman Medal – Emily Y. Chew, MD  
    9:08 a.m. Award Recipient – Maureen G. Maguire, PhD, FARVO  
         
      SESSION XIII - Oncology 2  
         
    9:15 a.m. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable
    Cancer Targets (MSK-IMPACT) of Retinoblastoma Tumors
    Jasmine Francis
    9:19 a.m. Discussion of Previous Paper  
    9:21 a.m. Follow the Nevus: The Cost-Utility of Screening for Growth of Choroidal Nevi William Smiddy
    9:30 a.m.  Small Choroidal Melanoma Managed by Plaque Radiotherapy in 1780 Cases:
    Visual Outcome and Millimeter Incremental Risk for Metastasis
    Carol Shields
    9:39 a.m. Clinical Features and Survival Outcome of 1111 Patients with Choroidal
    Metastasis Based on Primary Tumor Origin
    Jerry Shields
    9:48 a.m. Outcomes after Proton Irradiation for Patients Who are Eligible for
    Investigational AU-011 Treatment
    Evangelos Gragoudas
    9:57 a.m. Aflibercept for Radiation Maculopathy (ARM Study): A Prospective, Randomized
    Clinical Study with 2 year Outcome Analysis
    Timothy Murray
         
    10:10 a.m. Break  
         
      SESSION XIV - Other Macular Diseases  
         
    10:30 a.m. Longitudinal Changes in Eyes with Hydroxychloroquine Retinal Toxicity Catherine Cukras
    10:39 a.m. Topographic OCT Shows Limited Anatomic Recovery from Early
    Hydroxychloroquine Retinopathy
    Michael Marmor
    10:48 a.m. Association Between Industry Payments and Scholarly Impact Amongst
    Retina Specialists and Ophthalmologists
    Ron Adelman
    10:52 a.m. Anti-Enolase Drusen as a Subtype of Autoimmune Retinopathy Susumu Ishida
    10:56 a.m. Genes Associated with the Clinical Characteristics of Central Serous
    Chorioretinopathy
    Akitaka Tsujikawa
    11:00 a.m. Discussion of Previous Three Papers  
    11:03 a.m. Chronic Obstructive Sleep Apnea and Central Serous Chorioretinopathy:
    A Significant Association and Possible Mechanism
    Steven Schwartz
    11:12 a.m. Bruch’s Membrane and Myopic Axial Elongation Jost Jonas
    11:21 a.m. Exploring Retinal Mechanisms in Myopia: Photopic Electroretinogram
    Parameters and a Common Myopia Susceptibility Variant
    Omar Mahroo
    11:25 a.m. Digital Quantification of Metamorphopsia in Patients With Macular Disease:
    A Pilot Study
    Andrew Moshfeghi
    11:29 a.m. Discussion of Previous Two Papers  
         
      SESSION XV - Retinal Venous Occlusive Disease  
         
    11:32 a.m. Supernormal Flicker ERGs in Eyes with Central Retinal Vein Occlusion:
    Clinical Characteristics, Prognosis, and Effects of Anti-VEGF Agent
    Mineo Kondo
    11:36 a.m. A Novel Contrast Sensitivity Testing Device as a New Clinical Endpoint for
    Retinal Vein Occlusion
    John Miller
    11:40 a.m Discussion of Previous Two Papers  
    11:42 a.m. Patient-Reported Visual Function Outcomes after Anti-VEGF Therapy for
    Macular Edema due to CRVO or HRVO: Results from the SCORE2 Trial
    Ingrid Scott
    11:51 a.m. SD-OCT Predictors of Visual Outcomes after Ranibizumab Treatment for
    Macular Edema due to Retinal Vein Occlusion in the SHORE Study
    Glenn Yiu
    12:00 p.m. Long Term Outcomes of Eyes with Macular Edema Secondary to CRVO
    Treated with Intravitreal Bevacizumab. Real Life Experience of the
    Pan American Collaborative Retina Study (PACORES) Group
    Lihteh Wu
    12:09 p.m. Re-packaging Bevacizumab in 2-mL Glass Vials for Prolonged Sterility, Stability and Bio-activity Michael Ip
         
      SESSION XVI - Uveitis  
         
    12:20 p.m. Polymerase Chain Reaction in the Diagnosis of Toxoplasma Gondii
    Chorioretinitis
    Thomas Albini,
    12:24 p.m. Collaborative Ocular Tuberculosis Study (COTS) Consensus Guidelines on
    Initiating Antitubercular Therapy in Serpiginous Like Choroiditis
    Vishali Gupta
    12:28 p.m. Post-Surgical Versus Post-Intravitreal Injection Endophthalmitis:
    Changing Patterns in Causative Flora
    Matthew Simunovic
    12:32 p.m. Discussion of Previous Three Papers  
    12:34 p.m. Effect of Intravitreal Sirolimus on Visual Acuity in Subjects with Active Non-infectious
    Uveitis of the Posterior Segment of the Eye: Results of the SAKURA Program
    Brian Joodeph
    12:43 p.m. Periocular Triamcinolone vs. Intravitreal Triamcinolone vs. Intravitreal Dexamethasone
    Implant for the Treatment of Uveitic Macular Edema: The PeriOcular vs.
    INTravitreal Corticosteroids for Uveitic Macular
    Michael Altaweel
    12:52 p.m. Suprachoroidally Injected CLS-TA Results in Rapid and Sustained Resolution of
    Macular Edema in a Majority of Uveitis Patients: Results of the AZALEA,
    DOGWOOD, and PEACHTREE Studies
    Seenu Hariprasad
    1:01 p.m. Suprachoroidal CLS-TA Improves Visual Acuity and Macular Edema in
    Noninfectious Uveitis: Results of the Phase 3 PEACHTREE Study
    Steven Yeh
         
    1:04 p.m. Closing Remarks  
         
    1:10 p.m. Adjourn  
  • Hyatt Regency Coconut Point Resort and Spa

    The Macula Society
    3401 Enterprise Parkway Suite 310
    US - OH 44122 Cleveland, Ohio
    Tel.: +1 216 839 4949
    Fax: +1 216 831 8221

  •  

    Registration required. Please contact the organizer for further information.